Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X
Marvel Biosciences Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for its Lead Therapeutic Candidate MB-204
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
GoldInxs Mining Corp. Closes Second Tranche of Upsized Non-Brokered Private Placement and Announces Board Changes
RENFORTH INTERSECTS BROAD NICKEL-COBALT AND ZINC-COPPER-SILVER MINERALIZATION IN VICTORIA UNDERCUT DRILLING, INCLUDING 118.0 m OF 0.081% Ni AND 10.9 m OF 0.544% Zn
CoTec Holdings Corp. Notes HyProMag USA Deployment of Mobile Inserma System, Extending Hard Disk Drive Processing to Customer Sites Across the United States
Renforth Successfully Intersects Gold in Both Drillholes Undercutting Surface Gold Results within the 2025 MRE Pit Shell at Wholly Owned Parbec Gold Deposit in Malartic, Quebec
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
